Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

Biochemistry Research International is a prominent and dynamic journal published by Hindawi Ltd, dedicated to advancing knowledge in the field of biochemistry. With its Open Access model established since 2010, the journal provides unrestricted access to high-quality research, thereby fostering global communication among researchers and professionals. Operating out of the United States, Biochemistry Research International serves as a vital platform for disseminating cutting-edge findings in biochemistry and molecular biology, holding a respectable Q2 ranking in its category as of 2023. The journal's scope encompasses a wide array of topics including but not limited to biochemical processes, genetic engineering, and molecular interactions, making it an essential resource for students and seasoned researchers alike. With an impact factor reflective of its significance in the academic community, Biochemistry Research International continues to play an integral role in shaping the future of biochemistry research.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Neurochemical Journal, published by MAIK NAUKA/INTERPERIODICA/SPRINGER, focuses on the dynamic and rapidly evolving field of neurochemistry, providing insights into cellular and molecular neuroscience. Despite the discontinuation of its coverage in Scopus, the journal remains a valuable resource for researchers and professionals seeking to explore the biochemical underpinnings of neural function and pathophysiology. With an ISSN of 1819-7124 and an E-ISSN of 1819-7132, the journal aims to publish rigorous research articles, reviews, and notes that push the boundaries of our understanding of neurochemical processes. With a ranking that places its subjects in the lower quartile of their respective fields, Neurochemical Journal offers a platform for innovative studies and discussions among up-and-coming scientists, making it a crucial outlet for advancing the discourse in this critical area of biomedical research.

CELLULAR AND MOLECULAR NEUROBIOLOGY, published by SPRINGER/PLENUM PUBLISHERS, stands as a significant contributor to the fields of cell biology and neuroscience, holding a distinguished position in the academic community with an impact factor that places it in the Q2 category for both Cell Biology and Cellular and Molecular Neuroscience, along with Q1 in Medicine (miscellaneous). Since its inception in 1981, this journal has provided a critical platform for innovative research and thought-provoking reviews, fostering a deeper understanding of complex neurobiological mechanisms. The journal’s rigorous peer-review process ensures the publication of high-quality manuscripts that offer valuable insights into cellular processes and neural functions. With a commitment to advancing knowledge and promoting collaboration among researchers, CELLULAR AND MOLECULAR NEUROBIOLOGY remains an essential resource for professionals and students alike, looking to stay updated on the latest developments in neurobiology.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.